The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
In this episode of The Lead, host Sandeep A. Saha, MD, MS, FHRS, is joined by Babak Nazer, MD, and Rajesh Kabra, MD, FHRS, to discuss the journal article, Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study. Together, they review the study's six-month findings and explore the safety and effectiveness of a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.
Learning Objectives
- Review the six-month results of the FlexPulse IDE Study evaluating a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.
- Discuss the safety outcomes reported in the study and their implications for clinical practice.
- Examine the effectiveness findings of the dual-energy focal ablation approach in patients with paroxysmal atrial fibrillation.
Podcast Contributors
Sandeep A Saha, MD, MS, FHRS
Babak Nazer, MD
Rajesh Kabra, MD, FHRS
Host and Contributor Disclosure(s):
S. Saha
• Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Medtronic, Inc.
•Honoraria/Speaking/Consulting Fee: Edwards Lifesciences, Biosense Webster, Inc., Siemens Healthineers
•Research: Siemens Healthineers
R. Kabra
•Honoraria/Speaking/Consulting Fee: AtriCure, Inc., Biosense Webster, Inc., Milestone Pharmaceuticals, AltaThera Pharmaceuticals
•Research: Abbott Medical, Medtronic, Inc.